ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för niraparib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

32 träffar

Bibliografisk träff 2021-08-14

Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.

Sandhu D, Antolin AA, Cox AR, Jones AM.

Br J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1111/bcp.15015

Bibliografisk träff 2021-08-06

Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.

Leung JH, Lang HC, Wang SY, Lo HF, Chan AL.

Expert Rev Pharmacoecon Outcomes Res · journal article · DOI 10.1080/14737167.2021.1954506

Bibliografisk träff 2021-07-29

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.

Akce M, El-Khoueiry A, Piha-Paul SA, Bacque E, Pan P, Zhang ZY, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O'Bryant CL.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-021-04329-8

Bibliografisk träff 2021-07-09

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma.

Pletcher JP, Bhattacharjee S, Doan JP, Wynn R, Sindhwani P, Nadiminty N, Petros FG.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.681441

Bibliografisk träff 2021-05-31

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.

Jonuscheit S, Jost T, Gajdošová F, Wrobel M, Hecht M, Fietkau R, Distel L.

Genes (Basel) · research-article; journal article · DOI 10.3390/genes12060849

Bibliografisk träff 2021-05-17

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.

Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X.

J Ovarian Res · research-article; journal article; observational study · DOI 10.1186/s13048-021-00803-2

Bibliografisk träff 2021-05-01

Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib.

Wang J, Zhu J.

Ann Transl Med · research-article; journal article · DOI 10.21037/atm-21-2252

Bibliografisk träff 2021-04-26

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, Zhang X, Dong X, He J, Li X, Chen G, Li X, Zhang H, Liao W, Zhang Y, Ma Z, Jiang L, Cui J, Hu C, Wang W, Huang C, Zhao J, Ding C, Hu X, Wang K, Gao B, Song Y, Liu X, Xiong J, Liu A, Li J, Liu Z, Li Y, Wang M, Zhang B, Zhang D, Lu S.

J Thorac Oncol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jtho.2021.04.001

Bibliografisk träff 2021-04-24

NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.

Zhao X, Jiang L, Hu D, Tang Y, Zhao G, Du X, Luo S, Tang W.

Exp Cell Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.yexcr.2021.112614

Bibliografisk träff 2021-04-10

Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.

Bahar E, Kim JY, Kim DC, Kim HS, Yoon H.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22083916

Bibliografisk träff 2021-04-01

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.

Yonemori K, Shimizu T, Kondo S, Iwasa S, Koyama T, Kitano S, Sato J, Shimomura A, Shibaki R, Suri A, Kase Y, Sumino S, Tamura K, Yamamoto N.

Jpn J Clin Oncol · research-article; clinical trial, phase i; journal article · DOI 10.1093/jjco/hyab013

Bibliografisk träff 2021-03-28

PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.

Zhang N, Gao Y, Zeng Z, Luo Y, Jiang X, Zhang J, Li J, Zhang J, Gong Y, Xie C.

Clin Transl Oncol · journal article · DOI 10.1007/s12094-021-02591-z

Bibliografisk träff 2021-03-11

Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.

Liu MC, Sutedja J, Tewari KS.

Expert Rev Anticancer Ther · journal article; research support, n.i.h., extramural · DOI 10.1080/14737140.2021.1880326

Bibliografisk träff 2021-02-26

[New drug approval: Olaparib and niraparib - first line in ovarian cancer].

Delaye M, Rodrigues M.

Bull Cancer · letter · DOI 10.1016/j.bulcan.2021.01.003

Bibliografisk träff 2021-02-08

How to start niraparib in real-world Asian ovarian cancer patients?

Hong SH.

J Gynecol Oncol · comment; editorial · DOI 10.3802/jgo.2021.32.e36

Bibliografisk träff 2021-01-09

Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.

Ryan K, Bolaňos B, Smith M, Palde PB, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS.

J Biol Chem · research-article; journal article · DOI 10.1074/jbc.ra120.016573

Bibliografisk träff 2021-01-06

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

Vitiello PP, Martini G, Mele L, Giunta EF, De Falco V, Ciardiello D, Belli V, Cardone C, Matrone N, Poliero L, Tirino V, Napolitano S, Della Corte C, Selvaggi F, Papaccio G, Troiani T, Morgillo F, Desiderio V, Ciardiello F, Martinelli E.

J Exp Clin Cancer Res · research-article; journal article · DOI 10.1186/s13046-020-01811-8

Bibliografisk träff 2021-01-06

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.

Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N.

J Gynecol Oncol · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.3802/jgo.2021.32.e21

Bibliografisk träff 2021-01-01

Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.

Wang Q, Zhang F, Gao H, Xu Y.

Ann Palliat Med · journal article; case reports · DOI 10.21037/apm-21-113

Bibliografisk träff 2020-08-04

Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.

Barrington DA, Tubbs C, Smith HJ, Straughn JM, Senter L, Cohn DE.

Int J Gynecol Cancer · journal article · DOI 10.1136/ijgc-2020-001550

Bibliografisk träff 2020-07-25

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.

Li H, Tu J, Zhao Z, Chen L, Qu Y, Li H, Yao H, Wang X, Lee DF, Shen J, Wen L, Huang G, Xie X.

Theranostics · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/thno.45763

Bibliografisk träff 2020-07-14

Nephrotoxicity Associated With Niraparib.

Lazareth H, Delanoy N, Cohen R, Boissier E, Ayari H, Combe P, Crespel C, Mercadier-Riaz E, Karras A, Courbebaisse M, Thervet E, Pallet N.

Am J Kidney Dis · letter · DOI 10.1053/j.ajkd.2020.05.021

Bibliografisk träff 2020-02-25

Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.

Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, Clump DA, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, Skinner HD.

Int J Radiat Biol · research-article; journal article · DOI 10.1080/09553002.2020.1730014

Bibliografisk träff 2019-12-10

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.

Sahin ID, Jönsson JM, Hedenfalk I.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.27363

Bibliografisk träff 2018-08-01

Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods.

Gan N, Sun Q, Tang P, Wu D, Xie T, Zhang Y, Li H.

Spectrochim Acta A Mol Biomol Spectrosc · journal article · DOI 10.1016/j.saa.2018.07.100

Bibliografisk träff 2018-06-01

The role of niraparib for the treatment of ovarian cancer.

Ethier JL, Lheureux S, Oza AM.

Future Oncol · review; journal article · DOI 10.2217/fon-2018-0101

Bibliografisk träff 2017-11-29

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Sisay M, Edessa D.

Gynecol Oncol Res Pract · review-article; review; journal article · DOI 10.1186/s40661-017-0055-8

Bibliografisk träff 2017-07-12

Niraparib in ovarian cancer: results to date and clinical potential.

Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F.

Ther Adv Med Oncol · review-article; review; journal article · DOI 10.1177/1758834017718775

Bibliografisk träff 2016-12-21

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

Thorsell AG, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L, Moche M, Cohen MS, Schüler H.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.6b00990

Bibliografisk träff 2014-07-01

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.

Bridges KA, Toniatti C, Buser CA, Liu H, Buchholz TA, Meyn RE.

Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.2083